For Q3 of fiscal year ending March 2026, consolidated revenue was 3,411.2 billion yen (3.3% YoY decrease), operating income was 422.4 billion yen (1.2% YoY increase), and quarterly profit was 216.3 billion yen (2.4% YoY increase), leading to an upward revision of full-year earnings guidance.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4502","jir_company_name":"Takeda Pharmaceutical Company Limited","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-01-29","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/01\/4502-20260129-01.pdf","jir_short_summary":"For Q3 of fiscal year ending March 2026, consolidated revenue was 3,411.2 billion yen (3.3% YoY decrease), operating income was 422.4 billion yen (1.2% YoY increase), and quarterly profit was 216.3 billion yen (2.4% YoY increase), leading to an upward revision of full-year earnings guidance.","jir_summary":"### Performance Overview\nFor Q3 of the fiscal year ending March 2026, consolidated revenue was 3,411.2 billion yen (3.3% YoY decrease), mainly impacted by revenue decline due to generic penetration of the ADHD treatment VYVANSE in the Neuroscience segment. Meanwhile, the Gastrointestinal diseases, Plasma-Derived therapies, Oncology, and Vaccines segments posted revenue growth. Operating income increased slightly to 422.4 billion yen (1.2% YoY increase), with quarterly profit rising to 216.3 billion yen (2.4% YoY increase). Core operating income was 971.6 billion yen (3.4% YoY decrease), supported by cost reductions from efficiency programs. Regionally, revenue grew in Japan, Europe & Canada, and China, but declined in the United States.\n\n### Revision and Outlook of Full-Year Earnings Guidance\nFor the full fiscal year ending March 2026, consolidated earnings guidance has been revised upward to revenue of 4,530 billion yen (0.7% increase from previous forecast), operating income of 410 billion yen (2.5% increase), and net income of 154 billion yen (0.7% increase). The major driver of revenue growth is the forecasted weaker yen exchange rate, expected to partially offset the revenue decline from increased generic competition for VYVANSE. Core operating income guidance was also raised to 1,150 billion yen. While efficiency program cost savings are expected to continue, increased amortization expenses for intangible assets are anticipated to partially offset earnings growth.","jir_financial_highlights":"Revenue: 3,411.2 billion yen (3.3% YoY decrease)\nOperating Income: 422.4 billion yen (1.2% YoY increase)\nQuarterly Profit (Net Income Attributable to Owners of Parent): 216.1 billion yen (2.4% YoY increase)\nBasic Earnings Per Share (Quarterly): 137.31 yen (YoY increase)\nFull-Year Revenue Forecast: 4,530 billion yen (0.7% increase from previous forecast)\nFull-Year Operating Income Forecast: 410 billion yen (2.5% increase from previous forecast)\nFull-Year Profit Forecast (Net Income Attributable to Owners of Parent): 154 billion yen (0.7% increase from previous forecast)\nNumber of Outstanding Shares (End of Period): 1,590,987,809 shares (Almost flat YoY)\nNumber of Treasury Shares (End of Period): 11,391,398 shares (Decrease YoY)","jir_category":"","jir_hashtags":"#TakedaPharmaceutical, #FinancialSummary, #financial_summary, #JapaneseStocks","jir_key_figures":"Revenue: 3,411.2 billion yen (3.3% YoY decrease)\nOperating Income: 422.4 billion yen (1.2% YoY increase)\nQuarterly Profit (Net Income Attributable to Owners of Parent): 216.1 billion yen (2.4% YoY increase)","jir_meta_title":"Takeda Pharmaceutical Q3 Financial Summary for Fiscal Year Ending March 2026: Revenue 3,411.2 Billion Yen, Operating Income 422.4 Billion Yen (YoY)","jir_meta_description":"Takeda Pharmaceutical Q3 financial summary for fiscal year ending March 2026. Revenue was 3,411.2 billion yen (3.3% YoY decrease), operating income 422.4 billion yen (1.2% YoY increase), quarterly profit 216.3 billion yen (2.4% YoY increase). Full-year earnings guidance revised upward.","jir_og_title":"Takeda Pharmaceutical Announces Q3 Financial Results for Fiscal Year 2026","jir_og_description":"Revenue of 3,411.2 billion yen and operating income of 422.4 billion yen with year-over-year fluctuations. Upward revision to full-year earnings guidance.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend (100 million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Revenue\\\",\\\"data\\\":[35282,34112],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (100 million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[4175,4224],\\\"borderColor\\\":\\\"#28a745\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}}}}\"}, {\"jir_chart_id\": \"quarterly_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Quarterly Profit Trend (100 million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Quarterly Profit (Net Income Attributable to Owners of Parent)\\\",\\\"data\\\":[2111,2161],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Business Segment (100 million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Gastrointestinal\\\",\\\"Rare Diseases\\\",\\\"Plasma-Derived Therapies\\\",\\\"Oncology\\\",\\\"Vaccines\\\",\\\"Neuroscience\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q3 FY2025\\\",\\\"data\\\":[10393,5790,7842,4284,499,4565,1909],\\\"backgroundColor\\\":\\\"#6c757d\\\"},{\\\"label\\\":\\\"Q3 FY2026\\\",\\\"data\\\":[10786,5745,7905,4366,550,3145,1614],\\\"backgroundColor\\\":\\\"#007bff\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}}}}\"}, {\"jir_chart_id\": \"region_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Revenue by Region (100 million yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Japan\\\",\\\"United States\\\",\\\"Europe & Canada\\\",\\\"Latin America\\\",\\\"China\\\",\\\"Asia (Excluding Japan & China)\\\",\\\"Russia\/CIS\\\",\\\"Others\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q3 FY2025\\\",\\\"data\\\":[3247,18414,7956,1912,1338,754,619,1041],\\\"backgroundColor\\\":\\\"#6c757d\\\"},{\\\"label\\\":\\\"Q3 FY2026\\\",\\\"data\\\":[3395,16741,8326,1914,1411,729,605,991],\\\"backgroundColor\\\":\\\"#28a745\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"position\\\":\\\"top\\\"}}}}\"}]","ir_related_company":6852,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-21794","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n